Skip to main content
Elsevier

Breast Cancer, An Issue of Hematology/Oncology Clinics of North America

  • 1st Edition, Volume 37-1 - November 25, 2022
  • Latest edition
  • Editor: Harold J. Burstein
  • Language: English

In this issue of Hematology/Oncology Clinics, guest editor Dr. Harold J. Burstein brings his considerable expertise to Breast Cancer. Top experts provide a comprehensive update on… Read more

Purchase options

Info / Buy

Description

In this issue of Hematology/Oncology Clinics, guest editor Dr. Harold J. Burstein brings his considerable expertise to Breast Cancer. Top experts provide a comprehensive update on multidisciplinary management of early- and late-stage breast cancer, including key topics such as global perspectives on the epidemiology and treatment of breast cancer; breast cancer pathology in the era of genomics; optimizing radiation therapy after breast conserving surgery; and more.

Key features

  • Contains 16 relevant, practice-oriented topics including disparities in breast cancer outcomes and how to resolve them; genetic testing in breast cancer; the role of ovarian suppression in early stage premenopausal breast cancer; multidisciplinary management of brain metastases from breast cancer; evidence-based guidance for breast cancer survivorship; and more.

  • Provides in-depth clinical reviews on breast cancer, offering actionable insights for clinical practice.

  • Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create clinically significant, topic-based reviews.

Readership

Oncology

Table of contents

Disparities in Breast Cancer Outcomes and How to Resolve Them

Testing for Inherited Susceptibility to Breast Cancer

Breast Cancer Pathology in the Era of Genomics

Breast Cancer Pathology in the Era of Genomics

Role of Ovarian Suppression in Early Premenopausal Breast Cancer

Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer

Systemic Therapy for Early- and Late-Stage, Human Epidermal Growth Factor Receptor-2-Positive Breast Cancer

Biology and Treatment of HER2-Low Breast Cancer

Role of Immunotherapy in Early- and Late-Stage Triple-Negative Breast Cancer

Current and Emerging Role of Antibody–Drug Conjugates in HER2-Negative Breast Cancer

The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Multidisciplinary Management of Brain Metastasis from Breast Cancer

Systemic Therapy for Hereditary Breast Cancers

Evidence-Based Guidance for Breast Cancer Survivorship

Product details

  • Edition: 1
  • Latest edition
  • Volume: 37-1
  • Published: November 29, 2022
  • Language: English

About the editor

HB

Harold J. Burstein

Affiliations and expertise
Professor of Medicine, Harvard Medical School, Staff Physician, Brigham And Women's Hospital